Stockscreener 앱 받기
48.52
0.76%
-0.37
시간 외 거래:
48.20
-0.32
-0.66%
전일 마감가:
$48.89
열려 있는:
$48.91
하루 거래량:
790.85K
Relative Volume:
0.69
시가총액:
$3.85B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-8.1684
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
+5.64%
1개월 성능:
-2.02%
6개월 성능:
+10.57%
1년 성능:
+35.49%
1일 변동 폭
$48.02
$49.09
1주일 범위
$46.11
$49.15
52주 변동 폭
$28.72
$58.38
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.52 | 3.64B | 900.66M | -453.20M | -274.19M | -5.94 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Mackenzie Financial Corp Increases Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $74.00 at Wells Fargo & Company - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quantinno Capital Management LP Invests $436,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Toronto Dominion Bank Makes New $148.36 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
BNP Paribas Financial Markets Has $465,000 Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
State of Wyoming Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Two Sigma Investments LP Sells 143,945 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Woodline Partners LP Acquires Shares of 155,883 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Millennium Management LLC Has $13.97 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Bank of America Corp DE - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Holdings Lifted by ProShare Advisors LLC - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Cut by Two Sigma Advisers LP - MarketBeat
Voloridge Investment Management LLC Sells 92,168 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Price Target Raised by Wells Fargo | PTCT Stock News - GuruFocus
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
PTCT: Wells Fargo Increases Price Target for PTC Therapeutics | - GuruFocus
Evolving Landscape of Mitochondrial Disease Market: Key Insights of Latest Published Report—Leigh Syndrome, Leber’s Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency | DelveInsight - GlobeNewswire Inc.
PTC Therapeutics’ SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - Eastern Progress
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Deutsche Bank AG - MarketBeat
Rafferty Asset Management LLC Reduces Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Nuveen Asset Management LLC Acquires 273,638 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Lazard Asset Management LLC Has $2.06 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Muscular Dystrophy Treatment Market: Executive Briefing & - openPR.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51% - Yahoo Finance
StockNews.com Downgrades PTC Therapeutics (NASDAQ:PTCT) to Buy - MarketBeat
Point72 Asset Management L.P. Purchases 867,502 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Point72 Hong Kong Ltd Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 02 - marketscreener.com
14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Graham Capital Management L.P. - MarketBeat
Parkman Healthcare Partners LLC Decreases Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
2025-05-19 | PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PTCT | Press Release - Stockhouse
MPM Bioimpact LLC Buys 345,052 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results - Quantisnow
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down – Here’s What Happened - Defense World
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):